Premium
Mifepristone versus the Yuzpe regimen (PC4) for emergency contraception
Author(s) -
Ashok P.W.,
Hamoda H.,
Flett G.M.M.,
Templeton A.
Publication year - 2004
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2004.06.012
Subject(s) - mifepristone , medicine , regimen , gynecology , obstetrics , emergency contraception , pregnancy , population , family planning , research methodology , genetics , environmental health , biology
Objective: To compare side effects, women's acceptance and satisfaction with mifepristone (100 mg) versus the Yuzpe regimen for emergency contraception (EC). Methods: A total of 1000 women requesting EC within 72 h of unprotected intercourse were randomized to receive mifepristone 100 mg or the standard Yuzpe regimen. Outcome measures included patient acceptability and satisfaction. Results: A total of 620 (62%) questionnaires were returned, 64% in the mifepristone group and 60% in the Yuzpe group. Mifepristone was better tolerated than the Yuzpe regimen. The rates of nausea ( P <0.0001), abdominal pain ( P =0.001), tiredness ( P <0.0001), lethargy ( P =0.001), hot flushes ( P <0.0001) and dizziness ( P <0.0001) were all significantly higher in women given the Yuzpe regimen compared to those who received mifepristone. Of these 94% and 80% in the mifepristone and Yuzpe groups, respectively, were satisfied with treatment ( P <0.0001). Of women in the mifepristone group, 56% (181/321) had used the Yuzpe regimen of EC in the past and of these, 93.6% (161/172) indicated they would use mifepristone in the future. A total of four women in the Yuzpe group had mifepristone in the past and all four said they would use mifepristone in the future. Conclusion: Mifepristone has high patient acceptability and few side effects compared to the standard Yuzpe regimen for EC.